ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis)

Guo, Yuanli; He, Xinxin; Tan, Yanming; Liu, Junfeng; Chen, Huadong; Huang, Yi; Zhang, Chao; Tao, Ying*; Chen, Shan*广东药学院; 中山大学; 6; 1; y
Journal of Cancer Research and Clinical Oncology2023-11DOI: 10.1007/s00432-023-05341-6
10阅读
引用收藏
分享

摘要

Purpose Homologous recombination deficiency (HRD) plays a crucial role in ovarian cancer patients who are treated with Poly (ADP-ribose) polymerase inhibitors (PARPis). It could be defined as a prognosis biomarker. However, many high throughput sequencing methods for evaluating HRD, including HRDetect (WGS 10X), SigMA (WGS 40X or panel 1000X), and scarHRD (WGS 30X), are technically complex, time and data-storage consuming, and costly. Herein, we aimed to develop a low-cost method by low sequencing coverage to identify HRD status for precision medication. @@@ Methods We utilized ShallowHRD, a software tool to evaluate tumor HRD based on whole genome sequencing (WGS) at low coverage (1X), and established a novel scoring system, ShallowHRD score system. @@@ Results Compared with negative ShallowHRD status (ShallowHRD score < 15 or BRCA(wild)), positive ShallowHRD status (ShallowHRD score >= 15 or BRCA(mut)) presented favorable survival after being treated with PARPis. @@@ Conclusion The ShallowHRD status is a good biomarker for predicting prognosis, which could help guide the clinical application of PARPis in ovarian cancer patients by a cost-effective, time and data-storage saving method.

学科与关键词

关键词
Homologous recombination deficiencyPARPisWhole genome sequencingShallowHRDOvarian cancer
相关
加载中…
  • Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer
    Liu, Yang; Li, Yalun; Zhang, Min-Zhe; Chen, Dan; Leng, Yang; Wang, Juan; Han, Bo-Wei*; Wang, JiCANCER GENETICS, 2023, 272: 1-6.
  • Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
    Guffanti, Federica; Mengoli, Ilaria; Damia, Giovanna*Frontiers in Oncology, 2024, 14: 1405361.被引 2
  • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
    Zhang, Meng; Ma, Si-Cong; Tan, Jia-Le; Wang, Jian; Bai, Xue; Dong, Zhong-Yi*; Zhang, Qing-Xue*Frontiers in Oncology, 2021, 11: 772604.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Cancer Research and Clinical Oncology
发表日期
2023-11
卷期
第 149 卷, 第 17 期
页码
15839-15844
DOI
10.1007/s00432-023-05341-6
语言
ENGLISH
成果收录
SCIE
资助标注
Medical Science and Technology Research Foundation of Guangdong Province [20211118215153611]

作者

  • G

    Guo, Yuanli (第一作者)

    1 · guangdong pharmaceut univ

  • H

    He, Xinxin

    sun yat sen univ

查看全部 9 位作者收起作者
  • T

    Tan, Yanming

  • L

    Liu, Junfeng

    1 · sun yat sen univ

  • C

    Chen, Huadong

  • H

    Huang, Yi

  • Z

    Zhang, Chao

  • T

    Tao, Ying (通讯)

    1 · guangdong pharmaceut univ

  • C

    Chen, Shan (通讯)

    2 · 6 · sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417